World-first diabetes drug represents ‘a seismic shift’ in treatment

An insulin syringe draws insulin from insulin vial with glaucometer. A new drug targeting type 1 diabetes has been given the go ahead in the US (Alamy/PA)

The US approval of a drug that can delay the onset of type 1 diabetes represents the “start of a seismic shift” in treating the condition, a British charity has said

Teplizumab is a type of immunotherapy that works by tackling the root cause of diabetes rather than just its symptoms.